NVCT Nuvectis Pharma, Inc. Insider Trading

10% owner Mosseri bought 50,000 NVCT shares at $18.32 on 2026-06-30; stock now $19.47, up 99.7% in 30 days.

Mosseri, a 10% owner, purchased 50,000 shares for $916,000.00 at $18.32, increasing his holdings to 3,186,576 shares. The timing follows strong recent momentum: the stock has risen 99.7% over 30 days and 157.5% over 90 days from the transaction date, trading at $19.47 against a 52-week range of $5.55–$29.28. His prior trades at NVCT show mixed results—three of five prior buys achieved positive 90-day returns (+36.8%, +42.4%, +41.6%), though two experienced losses (-19.9%, -22.9%)—suggesting some capacity for opportunistic timing at this ticker. However, the company remains unprofitable with net income of $-6,050,000.00 and a market cap of $516,452,127.51, adding fundamental caution despite the insider's continued accumulation.

Ron Bentsur (CEO) bought 12,500 shares at $20.00 on 2026-06-30; stock now $19.47, down 33.5% from 52-week high but up 99.7% in 30 days.

Ron Bentsur's purchase of 12,500 shares at $20.00 follows a pattern of prior insider buys at NVCT where 4 of 5 earlier trades showed positive 90-day returns. His most recent buy on 2025-11-05 returned +17.3% in 30 days and +48.2% in 90 days; the 2024-12-24 buy returned +38.1% in 30 days and +111.0% in 90 days, demonstrating successful timing on near-term rallies at this ticker. The current transaction occurs as the stock has surged 99.7% in the last 30 days, having recovered sharply from a 52-week low of $5.55. However, investors should note the company remains unprofitable with net income of -$6,050,000.00 over its most recent full fiscal year, and the stock remains 33.5% below its 52-week high of $29.28. The timing of this buy into a momentum-driven rally, combined with the company's ongoing losses, creates tension between price-action signals and fundamental deterioration.

Director Sanchez Juan purchased 13,000 shares at $5.79; cluster buy pattern with 3 other insiders in past 14 days despite -48.4% from 52-week high.

Sanchez Juan, a Director, acquired 13,000 shares at $5.79 on 2025-11-05, increasing his holdings by 20.0% to 78,150 shares total. This purchase occurs within a broader pattern of insider accumulation: 3 other insiders also bought within the past 14 days. The timing is notable given the stock's current price of $5.67 is -48.4% from its 52-week high of $10.98, placing the transaction near recent lows. However, the company's fundamental position is challenged: it reported negative net income of $-7,462,000.00 over its most recent full fiscal year. The cluster buying pattern combined with significant share accumulation by multiple insiders warrants examination of whether this represents informed confidence in recovery or a coincidental purchasing period amid depressed valuation.

NVCT Chairman & CEO Bentsur buys 5,000 shares at $5.72 as stock down -48.4% from 52-week high; cluster of 4 insider buys in 14 days.

Ron Bentsur, as Chairman & CEO, purchased 5,000 shares at $5.72 on 2025-11-05, adding to holdings of 3.53M shares. The transaction occurs as NVCT trades -48.4% below its 52-week high of $10.98 and down -7.2% over the prior 30 days, against a backdrop of full-year net income of $-7,462,000.00. Notably, this buy is part of a cluster pattern: 3 other insiders also bought within the past 14 days. Bentsur's prior trades at NVCT show mixed timing results—3 of 5 prior buys ultimately produced positive 90-day returns, with his most recent buy on 2024-12-24 returning +111.0% over 90 days. However, his broader cross-ticker open-market history shows weaker predictive power: 20 prior buys averaging -17.8% return over 90 days with only a 15.00% win rate. The convergence of multiple insider purchases during a significant drawdown warrants investor attention to whether insiders perceive the decline as an opportunity, although the company's unprofitable state and the insider's mixed historical timing record limit conviction signals.

Director Kaplan Matthew L. buys 11,000 NVCT shares at $5.84; 3 insiders bought in past 14 days, stock down 48.4% from 52-week high, company unprofitable.

Director Kaplan Matthew L. purchased 11,000 shares at $5.84, expanding his stake by 9.7% to 124,760 shares post-transaction. This buy occurs alongside a cluster of 3 other insider purchases within the past 14 days, suggesting coordinated confidence at current levels. However, the purchase follows a significant decline: the stock trades at $5.67 versus a 52-week high of $10.98 (down 48.4%), and the company reported a full-year net loss of $-7,462,000.00, underscoring fundamental weakness. The timing of multiple insider buys against an unprofitable business in a steep drawdown warrants examination of whether this signals conviction in a turnaround or reflects contrarian positioning in a distressed situation.

10% owner Mosseri purchases 154,770 shares for $957.1K across 3 transactions at avg $6.18, raising stake 5.2% amid unprofitable operations.

Mosseri Marlio Charles, a 10% owner at Nuvectis Pharma, executed 3 separate purchases totaling 154,770 shares for $957,083.18 (blended average $6.18/share) between October 23–27, 2025, lifting his holdings from 2,981,806 to 3,136,576 shares. The purchases occurred at prices well below the 52-week high of $10.98 and modestly below the current price of $6.77. However, his prior trade history at this ticker shows a 0% well-timed rate across 5 prior buys—all five 90-day periods ended in losses ranging from −19.9% to −26.0%—suggesting a pattern of accumulation at inflection points that have not subsequently recovered. The company reported a net loss of $6,334,000 over its most recent full fiscal year, underscoring the speculative nature of the position at a $172.3M market cap. The purchases represent a material increase in an already substantial stake, warranting examination of whether this reflects conviction in a turnaround or continued accumulation of a deeply challenged asset.

10% owner Mosseri adds 5,603 shares at $7.99 amid -18.8% 30-day decline; NVCT unprofitable, stock -27.3% from 52w high

Mosseri, a 10% owner, purchased 5,603 shares at $7.99 on 2025-06-20, increasing holdings to 2,981,806 shares. This transaction occurred as the stock was down 18.8% over the prior 30 days and 27.3% below its 52-week high of $10.98. The company reported net income of -$5,332,000 in its most recent fiscal period, indicating ongoing unprofitability. Notably, Mosseri executed two prior purchases at NVCT on 2025-06-18 and 2025-06-17 (immediately preceding this transaction), suggesting a deliberate accumulation pattern over a concentrated window. His cross-ticker track record shows 20 prior open-market buys with an average 90-day return of -10.3% and a 22.22% win rate, indicating a history of purchases that have not consistently delivered positive outcomes at the 90-day horizon.

10% owner Mosseri purchases 33,442 shares ($269.5K) over 2 days at $8.06-$8.11, raising stake by 1.1%

Mosseri Marlio Charles, a 10% owner, executed two separate purchases totaling 33,442 shares for $269,532.04 on 2025-06-17 and 2025-06-18 at an average price of $8.06 per share. His post-transaction holdings of 2,976,203 shares now represent a 1.1% increase from prior position. The company is currently unprofitable with net income of $-5,332,000.00, and the stock has declined 19.1% over the prior 30 days and 26.0% from its 52-week high of $10.98. His cross-ticker track record shows 0 of 20 prior buys were well-timed on a 90-day basis (90d win rate 20.00%, avg 90d return -12.1%), though his same-ticker history at NVCT shows recent positive 30-day outcomes (+8.9% on 2025-05-12; +2.3% on three purchases on 2025-05-08), with this most recent purchase outcome not yet measurable.

10% owner Mosseri Marlio Charles bought 21,167 shares of NVCT at $8.11 on 2025-05-12; aggressive accumulation pattern in unprofitable biotech stock.

Mosseri purchased 21,167 shares on 2025-05-12 at $8.11, adding to a concentrated position that now totals 2,942,761 shares (2.94M shares). This transaction is part of a rapid accumulation sequence: the insider executed 5 separate purchases at NVCT between 2025-05-07 and 2025-05-12, suggesting deliberate position building over consecutive trading days. The company reported a net loss of $-5,332,000.00 ($-5.3M) over its most recent full fiscal year, and the stock currently trades at $8.43—approximately -23.2% from its 52-week high of $10.98. Across the insider's broader cross-ticker buy history, his average 90-day return has been -14.9% with a 90-day win rate of only 16.67%, indicating a weak track record of purchasing at opportune moments. The timing and intensity of purchases in an unprofitable company warrant close observation, particularly given the gap between transaction price and the 52-week highs.

10% owner Mosseri buys 27,411 shares across 3 days (May 6–8, 2025) for $235,647.22 at blended $8.60; stock now $8.99.

Mosseri Marlio Charles, a 10% owner, executed 8 separate purchases totaling 27,411 shares for $235,647.22 between May 6–8, 2025, at prices ranging from $8.40 to $8.65 (blended average $8.60). The current stock price of $8.99 represents a gain of approximately 4.5% from the blended transaction price. At the same-ticker level, his prior 5 NVCT purchases show mixed timing outcomes: the two most recent buys (Feb 2025 and Dec 2024) were followed by strong 90-day returns (+84.4% and +77.7%), while three earlier 2023 purchases each resulted in 90-day declines. The company remains unprofitable with net income of $-5,332,000.00 over the most recent full fiscal year, and the stock has declined 18.1% from its 52-week high of $10.98. The accumulation of 27,411 shares represents a 1.0% increase to his holdings (2.91M post-transaction), suggesting continued commitment to the position, though the modest size and recent unprofitability context limit confidence in forward returns.